Park Medi World eyeing nationwide impact with accelerated growth toward 5,000+ beds by FY28

IMT News Desk
IMT News Desk
· 3 min read
Hospital beds in a hospital room

Structured expansion across Delhi NCR, Uttar Pradesh and Punjab reinforces long-term vision to build a scaled, integrated healthcare platform

Park Medi World is accelerating a well-structured national growth strategy designed to build meaningful scale, deepen clinical capabilities, and deliver consistent, high-quality healthcare across diverse geographies. The group’s expansion is anchored in a long-term vision of creating a cohesive, national healthcare network that combines operational efficiency with strong clinical governance and patient-centric care.

As part of this broader vision, the company has recently strengthened its footprint across Delhi NCR,
Uttar Pradesh, and Punjab through the acquisition of KP Institute of Medical Sciences in Agra, Febris
Multispeciality Hospital in New Delhi, and Krishna Super-speciality Hospital in Punjab. Together, these
additions have expanded Park Medi World’s network by approximately 810 beds through strategic, all-
cash transactions, advancing the Group’s clearly articulated roadmap to scale beyond 5,000 beds by
FY28.

Importantly, these acquisitions are not viewed as standalone transactions, but as deliberate execution
milestones within a clearly defined national growth framework. Each asset has been evaluated through the lens of market relevance, clinical depth, integration readiness, and long-term value creation, ensuring that expansion remains both ambitious and disciplined.

In Western Uttar Pradesh, the integration of a large, multi-super-specialty facility strengthens Park Medi
World’s ability to deliver advanced tertiary care closer to patients in a high-potential market. In Delhi
NCR, expansion within dense urban and peri-urban catchments deepens access to organised, affordable
healthcare in one of the country’s most competitive healthcare corridors. In Punjab, the transition to full
ownership of an already stabilised hospital enables sharper execution, faster decision-making, and
deeper integration within the Group’s expanding network.

Together, these expansions underscore Park Medi World’s intent to scale decisively yet responsibly,
combining ambition with structure and speed with operating discipline, as it advances toward leadership
in North India’s organised healthcare sector.

Dr Ankit Gupta, Managing Director, Park Medi World, said, “Our vision is unambiguous: to build the most trusted, scalable, and clinically strong hospital network in North India. We are pursuing growth with intent and structure, not simply for size. Our expansion is guided by a clear national roadmap that allows us to scale efficiently while maintaining consistent clinical standards and strong governance across geographies. Every acquisition and expansion decision is anchored in long-term value creation by strengthening clinical depth, investing in medical talent, improving utilisation, and embedding operating discipline from day one. This enables us to grow aggressively, yet responsibly.As we move decisively toward a 5,000-plus bed platform by FY28, our focus is on building institutions that are resilient, outcome-driven, and deeply trusted by patients, clinicians, and communities. We believe this combination of scale, structure, and clinical excellence will define the next phase of healthcare leadership in North India.”

Read Next

Centre Reaffirms Commitment to Building Healthcare Infrastructure Across Northeast India; Nadda Inaugurates Super-Specialty Hospital in Meghalaya
News
June 5, 2026

Centre Reaffirms Commitment to Building Healthcare Infrastructure Across Northeast India; Nadda Inaugurates Super-Specialty Hospital in Meghalaya

Union Health Minister J P Nadda on Thursday declared that the Central Government remains firmly committed to strengthening healthcare infrastructure across the Northeast and ensuring that advanced medical services reach people living in remote and underserved areas of the region. Nadda made these remarks while inaugurating ARHI Hospital in Meghalaya’s Ri-Bhoi district- a new super-specialty […]
Article by: IMT News Desk
Hexagon Nutrition Raises Rs 41.66 Crore from Anchor Investors Ahead of Rs 139-Crore IPO Opening Today
News
June 5, 2026

Hexagon Nutrition Raises Rs 41.66 Crore from Anchor Investors Ahead of Rs 139-Crore IPO Opening Today

Mumbai-based Hexagon Nutrition Ltd has mobilised Rs 41.66 crore from anchor investors ahead of its initial public offering (IPO), which opened for public subscription on June 5 and will remain open until June 9, 2026. According to a circular uploaded on BSE’s website, the company allotted a total of 92.57 lakh equity shares to anchor […]
Article by: IMT News Desk
Otsuka’s Voyxact Shows Kidney Function Preservation in Late-Stage IgAN Trial, Setting Stage for Full FDA Approval
News
June 5, 2026

Otsuka’s Voyxact Shows Kidney Function Preservation in Late-Stage IgAN Trial, Setting Stage for Full FDA Approval

Otsuka Pharmaceutical has reported that its approved kidney disease drug Voyxact (sibeprenlimab) preserved kidney function over 12 months in a late-stage clinical study, marking a significant milestone in the treatment of immunoglobulin A nephropathy (IgAN), a serious autoimmune condition that progressively damages the kidneys. In the Phase 3 VISIONARY trial involving 320 participants, patients who […]
Article by: IMT News Desk
Akums Receives European CEP Approval for Cefpodoxime Proxetil
News
June 4, 2026

Akums Receives European CEP Approval for Cefpodoxime Proxetil

Akums Drugs & Pharmaceuticals Ltd. has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for its active pharmaceutical ingredient (API), Cefpodoxime Proxetil. The CEP certification confirms that Akums’ manufacturing process and quality standards for Cefpodoxime Proxetil comply with the requirements of the European Pharmacopoeia. The […]
Article by: IMT News Desk